Stuttering, a challenging speech disorder, often brings deep embarrassment to those it affects. For years, a leading U.S. psychiatrist has championed an experimental drug as a potential breakthrough treatment.
Stuttering disrupts speech rhythm through involuntary repetitions and prolongations of sounds, syllables, words, or phrases, along with abrupt pauses where no sound emerges. The World Health Organization (WHO) defines it as "speech characterized by frequent repetition of sounds and syllables or by frequent hesitations or pauses, for at least 3 months." It's classified among emotional or behavioral disorders.
Affecting roughly 70 million people worldwide, stuttering drives cutting-edge research into brain mechanisms. Gerald Maguire, MD, a psychiatry expert at the University of California, Riverside, zeroes in on dopamine. This neurotransmitter, often called the "happiness hormone," speeds up or slows neuron firing depending on the nerve receptor it binds to.
Since the 1990s, Dr. Maguire's team has used scintigraphy—a brain imaging technique measuring blood flow—on people who stutter. Scans consistently showed excessive dopamine activity, inspiring him to explore dopamine blockers as a remedy.
In prior trials, Dr. Maguire tested antipsychotics to inhibit dopamine, yielding benefits but also side effects like weight gain, muscle stiffness, and depression, which prevented FDA approval for stuttering. Then, in August 2019, he shared breakthrough data on ecopipam via Europe PubMed Central.
Ecopipam targets specific dopamine receptors. A small trial with about a dozen participants demonstrated markedly improved speech fluidity. These results fuel Dr. Maguire's optimism for a forthcoming larger-scale trial.
